✦ LIBER ✦

Intrahepatic interferon-stimulated gene responses: Can they predict treatment responses in chronic hepatitis C infection?

✍ Scribed by Nicholas A. Shackel; Geoffrey W. McCaughan

Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 343 KB
Volume: 46
Category: Article
ISSN: 0270-9139
DOI: 10.1002/hep.22006

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Early Hepatitis C virus–RNA responses pr

Early Hepatitis C virus–RNA responses predict interferon treatment outcomes in chronic hepatitis C

✍ William M. Lee; K. Rajender Reddy; Myron J. Tong; Martin Black; Dirk J. van Leeu 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 100 KB 👁 2 views

In previous studies employing interferons (IFNs) in the treatment of chronic hepatitis C, there have been few reliable predictors of sustained responses. We retrospectively evaluated the predictive value of hepatitis C virus (HCV)-RNA measurements in the first few months during consensus interferon

Immune response in chronic hepatitis C–i

Immune response in chronic hepatitis C–infected patients undergoing interferon treatment

✍ Antonietta Cargnel; Guido Gubertini; Carlo Magnani; Simona Bosis; Fulvia Colombo 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 24 KB 👁 1 views

The findings of Mason et al. 1 on diabetes mellitus and hepatitis C are similar to our own, reported at the 8th European Congress of Clinical Microbiology and Infectious Diseases. 2 In our study, diabetes was found in 34.7% and 2.7% of chronic hepatitis C and chronic hepatitis B patients, respective

Isolated anti-HBc in chronic hepatitis C

Isolated anti-HBc in chronic hepatitis C predicts a poor response to interferon treatment

✍ Evangelista Sagnelli; Nicola Coppola; Carlo Scolastico; Anna Rita Mogavero; Mari 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 128 KB 👁 1 views

## Abstract The sustained response to interferon‐α treatment was evaluated in 147 anti‐HCV/HCV‐RNA‐positive, HBsAg‐negative, chronic hepatitis patients, according to HCV genotypes and the presence or absence of anti‐HBs and anti‐HBc. These patients had been included in a controlled study on the saf

Anti-envelope 1 and 2 immune response in

Anti-envelope 1 and 2 immune response in chronic hepatitis C patients: Effects of hepatitis B virus co-infection and interferon treatment

✍ Rosa Zampino; Aldo Marrone; Emanuele Durante Mangoni; Lucio Santarpia; Antonello 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB 👁 1 views

## Abstract Antibodies against envelope glycoprotein 1 and 2 (anti‐E1/E2) have been suggested to influence HCV replication levels. Hepatitis B virus (HBV) may interfere with hepatitis C virus (HCV) replication. At present there are no data on anti‐E1/E2 antibody responses or on the effect of interf

Is serum uric acid a predictive factor o

Is serum uric acid a predictive factor of response to IFN-treatment in patients with chronic hepatitis C infection?

✍ Rinaldo Pellicano; Giovanni Puglisi; Alessia Ciancio; Federico Balzola; Giorgio 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 87 KB

## Abstract Several factors, including metabolic profile, are predictive of response to standard antiviral therapy in patients with chronic hepatitis C. In a retrospective study, it was investigated whether uric acid, involved in metabolic syndrome, could be included. A total of 153 patients (56.2%

Variants in interferon-alpha pathway gen

Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial

✍ Tania Mara Welzel; Timothy R. Morgan; Herbert L. Bonkovsky; Deepa Naishadham; Ru 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 270 KB 👁 2 views

Combination treatment with pegylated-interferon-alpha (PEG IFN-␣) and ribavirin, the current recommended therapy for chronic hepatitis C virus (HCV) infection, results in a sustained virological response (SVR) in only about half of patients. Because genes involved in the interferon-alpha pathway may